TriangleAsparaginase Erwinia chrysanthemi (NCT06918431)
Asparaginase Erwinia chrysanthemi trial for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative (NCT06918431). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people with newly diagnosed, Philadelphia-negative acute lymphoblastic leukemia or lymphoblastic lymphoma: ages 18–39 with BMI at least 30, or ages 40–54 regardless of BMI. B-cell or T-cell disease qualifies.
The idea: recombinant Erwinia asparaginase removes asparagine that cancer cells need. Patients receive muscle injections alongside induction chemotherapy, including spinal-fluid treatment. Rituximab is added only for CD20-positive disease. Consolidation asparaginase is optional. Researchers assess safety and liver toxicity; previous asparaginase is excluded.
This phase 2 study plans 53 patients. Ibrahim Aldoss leads City of Hope; four US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.